Destiny fulfilled: Fate prices $40m IPO
This article was originally published in Scrip
It took a couple of tries to find the right price for an initial public offering, but Fate Therapeutics priced 6.7m shares at $6 each for gross proceeds of $40m on 1 October to fund its hematopoietic stem cell (HSC) and satellite stem cell (SSC) modulation platforms.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.